2014 Corn Belt Crop Tour - AgReliant Genetics Interview
2014 Corn Belt Crop Tour -- Interview with Tom Koch, Vice President of Research with AgReliant Genetics. Farms.com Risk Management Chief Commodity Strategist, Maurizio Agostino talks with Tom...

By: FarmMarkets

Go here to see the original:
2014 Corn Belt Crop Tour - AgReliant Genetics Interview - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research

Because the adult mammalian central nervous system has only limited intrinsic capacity to regenerate connections after injury, due to factors both intrinsic and extrinsic to the mature neuron, therapies are required to support the survival of injured neurons and to promote the long-distance regrowth of axons back to their original target structures. The retina and optic nerve are part of the CNS and this system is much used in experiments designed to test new ways of promoting regeneration after injury. Testing of therapies designed to improve RGCs viability also has direct clinical relevance because there is loss of these centrally projecting neurons in many ophthalmic diseases. Many different approaches are being trialed, targeting different receptor systems and/or different signaling pathways, some aimed at enhancing intrinsic growth capacity in injured RGCs, others aimed at reducing the impact of factors external to the neuron that suppress/restrict the regenerative response. An approach increasingly of interest involves the use of modified, replication-deficient viral vectors to introduce appropriate genes into injured cells in the visual pathway (gene therapy).

In the perspective article written by Prof Alan Harvey, from School of Anatomy, Physiology and Human Biology, The University of Western Australia, he summarized recent gene therapy research from his laboratory, using the rodent visual system as an experimental model, which is aimed at improving both the viability and regenerative capacity of injured adult RGCs. These perspectives were published in the Neural Regeneration Research (Vol. 9, No. 3, 2014).

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read more:
Gene therapy and the regeneration of retinal ganglion cell axons

Recommendation and review posted by Bethany Smith

2014 P1 English Course Final presentation "Personalized Medicine"
2014 1 This video shows a final presentation of a freshman. He is talking about "Personalized...

By: ProjectBasedEnglish

Go here to see the original:
2014 P1 English Course Final presentation "Personalized Medicine" - Video

Recommendation and review posted by sam

Top 16 Safe Alzheimer Stem Cell Therapy Options Worldwide
The cure for Alzheimer #39;s has not yet been found, yet, the miraculous stem cells have been effective in treating the symptoms of the disease and re-establishing neural connections. Available...

By: placidways

Visit link:
Top 16 Safe Alzheimer Stem Cell Therapy Options Worldwide - Video

Recommendation and review posted by simmons

Stem Cell Therapy and Platelet Rich Plasma (PRP) Therapy

By: DR Kyle Kinmon

Read the original:
Stem Cell Therapy and Platelet Rich Plasma (PRP) Therapy - Video

Recommendation and review posted by simmons

Council of Scientific and Industrial Research (CSIR) Centre for Cellular and Molecular Biology (CCMB) Director, Dr Ch. Mohan Rao today claimed that the heart disease can be treated without surgeries in future.

Addressing after inaugurating the 19th Annual conference of the Cardiological Society of India (CSI-AP Chapter) here, Dr Rao said that in the recent research in molecular biology found that 'heart' too have 'stem cells' which will help to automatically build the damaged part of any organ.

He said that further research also going with collaboration of other foreign institutions on how to bring the 'stem cells' out and repair.

Once the solution is found, the cardiac diseases can be healed with surgery, Dr Rao said.

''This development will make the stem cell based therapy replace the chemical based therapy in Cardiology,'' he added.

Irregular eating habits and busy lifestyle are among the major causes of the cordial illness, he said and advised to the youth to follow healthy lifestyle to avoid heart related problems.

While talking about the latest research, he said, ''To reduce the deaths due to cardiac illness the CCMB is working along with the scientists from Japan, the US and Italy to develop the an easier way to treatment.''

Dr Rao also given a clarion call to Cardiology experts to come forward for joint research on cardiac problems.

Encouraging the research in Cardiology, Dr Rao also invited the young medicos to visit the CCMB campus and work with the institute.

Discussing various kinds of heart diseases, he said, ''Dilated Cardiomyopathy is one of the most common heart disease among the children.''

Read more:
Cardiac diseases to be treated without surgeries soon as stem cells found

Recommendation and review posted by Bethany Smith

Federal funding blocked mainly over opposition to use of blastocysts

PORTSMOUTH Dr. Amy Sievers, an oncologist at Portsmouth Regional Hospital, does stem cell transplants with great success for her patients and is a firm advocate for stem cell research.

Sievers is allowed to do stem cell blood transplants because she does not use the source of controversy, embryonic stem cells. Instead, she can use stem cells from bone marrow, where blood is made. The cells can become new blood for transfusion into patients with blood-related cancers like leukemia.

"When we get past the chemo and radiation, the hope is we can replace blood and give the patient healthy blood and a chance to build a good immune system," Sievers said.

Parents saving cord blood when they give birth is an option, but Dr. Alexandra Bonesho of Core Physicians in Epping said it is very costly for the patient, is not covered by insurance and is not something pediatricians recommend widely unless there is a reason.

"It's not something we use as a practical course of events," Bonesho said. "Cord blood banking is very expensive, less so if the blood stem cells are donated to the National Cord Blood Bank. In most cases, the chance that you will need it for your own child is unlikely, unless there is already a known condition in the family."

For example, if there is a history of leukemia in another child, it may be worthwhile. Bonesho said in a case like that, having the baby's own blood stem cells can be the perfect answer.

"However, chances are good that if there is a sibling, they may also be a good match if a bone marrow transplant is needed," Bonesho said. "However, transplants are not the normal course of treatment in children with leukemia."

That being said, the cord blood could eventually be used for research in the future to find a cure for diseases like sickle cell anemia, Bonesho said.

Federal funding for much stem cell research is blocked mainly over the opposition to using embryonic stem cells. The cells come from blastocysts (fertilized eggs) from an in-vitro facility. The blastocysts are excess and are usually donated by people who have already been successfully treated for fertility problems.

Originally posted here:
The promise and hazards of stem cell research

Recommendation and review posted by Bethany Smith

The Night Shift Anatomy of a Night Shift Scene (Behind-The-Scenes) Get an insider's look at the production of a remarkable scene from The Night Shift episode Storm Watch. Subscribe for more The Night Shift!: http://bit.l

By: The Night Shift

Read this article: The Night Shift Anatomy of a Night Shift Scene (Behind-The-Scenes) Video

Infomercial Production Best Infomercial for Nanotechnology Infomercial Production. This is still one of the best nanotechology applications which hit TV through this infomercial production. Infomercial production companies are still great at showcasing

By: Quantum Ad Ventures Inc.

Read the original here: Infomercial Production Best Infomercial for Nanotechnology Video

Spitali Medicine TV ad 33 sec Client: Spitali Medicine Concept and Production: Ikon Studio.

By: Ikon Studio

Originally posted here: Spitali Medicine TV ad 33 sec Video

NEW YORK, June 18 2014 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue: Biotechnology in Food Production Market Forecast 2014-2024 http://www.reportlinker.com/p02148717/Biotechnology-in-Food-Production-Market-Forecast-2014-2024.html

More here:
production IPS Cell Therapy IPS Cell Therapy

Recommendation and review posted by Bethany Smith

Gene Therapy Program > Home

Providing a foundation for basic research necessary to assure the success of gene therapy.

Given all the developments in molecular genetics, the isolation and cloning of genes is now a relatively common procedure. Research now centers on somatic gene therapy, referring to the techniques used to insert a functioning gene into the somatic (non-reproductive) cells of a patient to correct an inborn genetic error or to provide a new function to the cell. Having individual genes available opens the way for gene therapy to take place. And yet, after an initial period of about six years of preclinical work and another thirteen years involving clinical trials, effective gene delivery still remains one of the central challenges in the field.

The Gene Therapy Program of the University of Pennsylvania comprises basic scientific research and core lab research services. Our focus is on developing effective gene vectors derived from recombinant viruses. Much of our current effort is in the development of new adeno-associated virus (AAV) vectors, although some of our research involves both adenoviruses and lentiviruses. Several basic science core laboratories work together to support the development of new vectors.

Contact: Gene Therapy Program Suite 2000, Translational Research Laboratories (TRL) 125 S. 31st Street Philadelphia, PA 19104-3403 Phone: 215-898-0226 Fax: 215-494-5444 GTP@mail.med.upenn.edu

Original post:
University of Pennsylvania || Gene Therapy Program

Recommendation and review posted by Bethany Smith

Genetic disorders have been plaguing people for ages and causing fatalities. However, with new information and research, and something called gene therapy, hope now exists for these unfortunate individuals. Gene therapy is a technique for correcting defective genes responsible for disease development. It has been around for a while now and is getting more advanced with time. Experimentation is an ongoing process with gene therapy. Ethical issues are something that has been accompanying the procedure since it has been used. New facts on gene therapy continue to be uncovered as we speak. To start off, an overview of why people need gene therapy should be covered. Each of us carries about half a dozen defective genes. However, we remain ignorant to this fact unless we are among the millions of people who have a genetic disorder. About one in ten people has, or will develop some time later in life, an inherited genetic abnormality. And approximately two thousand eight hundred specific conditions are known to be caused by defects in just one of the patients genes. Some single gene disorders are pretty common, such as cystic fibrosis. Most people do not suffer harmful effects from our defective genes because we carry two copies of nearly all genes. One is inherited from our mother and the other from our father. The only exceptions to this rule are the genes found on the male sex chromosomes. Males have one X and one Y chromosome, the former from the mother and the latter from the father. So each cell has only one copy of the genes on these chromosomes. In the majority of cases, one normal gene is enough to avoid all the symptoms of disease. If the gene that may be harmful is recessive, then its normal counterpart will carry out all the tasks assigned to both. A disease will develop only if someone inherits two copies of the recessive gene from their parents. (Web source #3) In other terms, if the gene is dominant, it alone can produce the disease, even if the counterpart is normal. Finally, there are the X chromosome-linked genetic diseases. Because males have only one copy of the genes from this chromosome, there are no others available to fulfill the defective genes function. Hemophilia is a common result of this. To continue, how gene therapy works, should be explained. There are several different approaches scientists may use to correct faulty genes with therapy. One method is that a normal gene may be inserted into a nonspecific location within the genome to replace a nonfunctional gene. This happens to be the most common approach utilized. Another method is an abnormal gene could be exchanged for a normal gene through homologous recombination. (Web source #2) Also, the abnormal gene could be repaired through selective reverse mutation, which would restore the gene to its original function. Finally, the regulation or degree to which a gene is turned on or off, of a particular gene could be altered. In the majority of gene therapy studies, a normal gene is inserted into the genome to replace an abnormal, disease-causing gene. A carrier molecule called a vector must be used to deliver the therapeutic gene to the patients target cells. Currently, the most common vector is a virus that has been genetically altered to carry normal human DNA. Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner. Scientists have tried to take advantage of this capability and manipulate the virus genome to remove disease causing agents and insert therapeutic genes. There are a series of different types of viruses used as gene therapy vectors. One is adenoviruses. These are a class of viruses with double-stranded DNA genomes that cause respiratory, intestinal and eye infections in humans. The virus that causes the common cold is an adenovirus. Another type is retroviruses. This is a class that can create double-stranded DNA copies of their RNA genomes. These copies of its genome can be integrated into the chromosomes of host cells. HIV is a retrovirus. A third type is adeno-associated viruses, which are a class of small, single-stranded DNA viruses that can insert their genetic material at a specific site on chromosome nineteen. One more type is herpes simplex viruses. This is a class of double-stranded DNA viruses that infect particular cell type, neurons. Herpes simplex virus type one is a common human pathogen that causes cold sores. Besides, virus mediated gene-delivery systems, there are several nonviral options for gene delivery. The simplest method is the direct introduction of therapeutic DNA into target cells. Another nonviral approach involves the creation of an artificial lipid sphere with an aqueous core. (Web source #2) Today, the current status of gene therapy is unofficial. In fact the Food and Drug Administration has not yet approved any human gene therapy product for sale. Gene therapy is currently experimental and has not quite been proven completely successful in clinical trials. For example, little forward progress has been achieved since the first gene therapy experimental trial began in 1990. A major setback was suffered in 1999 when the death of an 18-year-old named Jesses Gelsinger occurred. He was participating in a clinical trial for ornithine transcarboxylase deficiency, or OTCD. Jesses death is believed to have been triggered by a severe immune response to the adenovirus carrier. FDAs Biological Response Modifiers Advisory Committee met at the end of February 2003 to discuss possible measures that could allow a number of retroviral gene therapy trials for treatment of life-threatening diseases to proceed with appropriate guide lines. (Web source #2) There are certain factors that have kept gene therapy from becoming an effective treatment for genetic diseases. One is the short-lived nature of gene therapy. Before gene therapy can become a permanent cure for any condition, the therapeutic DNA introduced into target cells must remain functional and the cells containing the therapeutic DNA must be long-lived and stable. (Web source #2) Problems with integrating therapeutic DNA into the genome and the rapidly dividing nature of many cells prevent gene therapy from achieving any long-term benefits. Patients will have to undergo numerous rounds of gene therapy. Another factor is immune response. Anytime a foreign object is introduced into human tissues, the immune system is designed to attack the invader. The risk of stimulating the immune system in a way that reduces gene therapy effectiveness is always a potential risk. (Web source #2) Furthermore, the immune systems enhanced response to invaders it has seen before makes it difficult for gene therapy to be repeated in patients. Another setback is problems with viral vectors. Viruses, while the carrier of choice in most gene therapy studies, present a variety of potential problems to the patient which include toxicity, immune and inflammatory responses, and gene control and targeting issues. In addition, there is always the fear that the viral vector, once inside the patient, may recover its ability to cause disease. One more problem is multigene disorders. Conditions or disorders that arise from mutations in a single gene are the best candidates for gene therapy. Unfortunately, some of the most commonly occurring disorders, such as heart disease, high blood pressure, arthritis, and diabetes are caused by the combined effects of variations in many genes. Multigene or multifactoral disorders such as these would be especially difficult to treat effectively using gene therapy. (Web source #2) There is current progress being made with gene therapy, however. In reference to the Human Genome Project, the mapping out of the makeup of all human genes, another gene has recently been successfully analyzed. Scientists in Britain have finished work on human chromosome six which contains genes linked to the bodys immune response against bacteria and viruses. Comprising nearly six percent of the entire human genome, it is the largest of the twenty three pairs of human chromosomes completed so far. (Web source #1) Chromosome six is very concentrated in immune genes. These are the genes that give us protection from pathogens. With this new knowledge, there is now a boost for organ transplants These immune genes are particularly important for transplant medicine because doctors will be better able to match donor organs and recipients. About 1,557 genes on chromosome six are thought to be functional. Roughly 130 genes have been identified that somehow cause or predispose humans to certain diseases. (Web source #1) Knowing all of this information will help scientists in the future to learn how to altar these genes in order to prevent these diseases from taking place. In addition, ethical issues are coincidently always brought up with gene therapy. A common question is what is normal and what is a disability or disorder, and who decides? This is a very pressing question that will remain as long as gene therapy does. Whether it is the parents, the governments or the patients right to decide what goes forth is a tough concept. Another ethical issue is preliminary attempts at gene therapy are extremely expensive. Who will have access to these therapies and who will pay for their use? This is a very difficult question to derive an answer to. A fairness issue arises when only the very wealthy are the ones able to receive clinical trials of the medicines used in gene therapy. Also, the question of are disabilities diseases and do they need to be cured or prevented comes up. I believe it is up to the individual person to decide whether or not treatment is necessary but there may be exceptions. One more popular issue brought up with gene therapy is does searching for a cure demean the lives of individuals presently affected by disabilities? This is a question that can only be solved through personal research with actual patients or individuals. (Web source #2) In conclusion, although currently an unofficial form of treatment, gene therapy holds promise for the future. The Human Genome continues to be mapped and the more that is analyzed, the further research can be taken. Progress is being made, and despite setbacks along the way, the achievements seem to outweigh the failures. Progress will hopefully continue so that genetic disorders may someday be unheard of with the help of gene therapy and a better understanding of human genetics.

Works Cited 1.http://my.aol.com/news.news_stories 2.http://www.ornl.gov/techresources/humangenome/medicine/genetherapy.html 3. http://www.accessexcellence.org/AB/IWT/gene_therapy.overview.html

Originally posted here:
Gene therapy :: essays research papers fc

Recommendation and review posted by Bethany Smith

Illuminati Science EXPOSED Genetic Engineering, Cloning, DNA Manipulation, Transhumanism
The elite are developing technology and sciences to be able to be like God. They are looking to have the same creative power as God and be able to create life. In this video I expose the plans...

By: TheVigilantChristian

See the original post here:
Illuminati Science EXPOSED Genetic Engineering, Cloning, DNA Manipulation, Transhumanism - Video

Recommendation and review posted by Bethany Smith

MARTINOTTI FRANCESCO - CUSTOM GENETICS
APCR Tappa IV 2014 - Open.

By: Studio di Fotografia Andrea Bonaga

Read more:
MARTINOTTI FRANCESCO - CUSTOM GENETICS - Video

Recommendation and review posted by Bethany Smith

Robert Downey Jr Son #39;s Arrest Intervention Indio Downey Addiction Genetics Factor Challenge
Robert Downey Jr Son #39;s Arrest Intervention Indio Downey Addiction Genetics Factor Challenge. Robert Downey Jr. #39;s son Indio is in trouble with the law. Indio ...

By: newsbrakes

Here is the original post:
Robert Downey Jr Son's Arrest Intervention Indio Downey Addiction Genetics Factor Challenge - Video

Recommendation and review posted by Bethany Smith

Myth 9: Alzheimer #39;s is all about genetics.
Q. My father died from early-onset Alzheimer #39;s Disease. Will I definitely get it? A. That #39;s a question I hear alot when we do assessments for people who are ...

By: PineRestVideo

Read the original:
Myth 9: Alzheimer's is all about genetics. - Video

Recommendation and review posted by Bethany Smith

Robert Sapolsky - The complexity of genetics
5. Molecular Genetics II http://www.youtube.com/watch?v=dFILgg9_hrU 00:46:34 - 00:47:56.

By: Mind.Blown

Here is the original post:
Robert Sapolsky - The complexity of genetics - Video

Recommendation and review posted by Bethany Smith

National Conference of Regenerative Medicine and Surgery
The actual status of the future medicine.

By: Adrian Marinescu

Read more from the original source:
National Conference of Regenerative Medicine and Surgery - Video

Recommendation and review posted by sam

July 5, 2014

redOrbit Staff & Wire Reports Your Universe Online

According to a new study appearing in the July 3 edition of the journal Cell Stem Cell, researchers from the Johns Hopkins University School of Medicine have uncovered a new genetic variant that could result in certain people having a predisposition to schizophrenia.

While there are many genetic variants that could increase the risk of developing a psychiatric disorder, they are insufficient to cause these diseases, the researchers explained. Now, however, the Johns Hopkins researchers have described a new strategy that could reveal how these so-called subthreshold genetic risks could impact the development of a persons nervous system by interacting with other risk factors.

This is an important step toward understanding what physically happens in the developing brain that puts people at risk of schizophrenia, senior author Dr. Guo-li Ming explained in a statement Thursday. Dr. Ming is a professor of neurology and neuroscience in the Johns Hopkins University School of Medicines Institute for Cell Engineering who worked on the study along with her husband, Dr. Hongjun Song.

In their study, Dr. Ming, Dr. Song and their colleagues explained that they used a multifaceted approach to find out why copy number variants in an area of the genome labeled 15q11.2 are prominent risk factors not just for schizophrenia, but for autism as well. Deletion of this part of a genome is associated with an increased risk of schizophrenia, but possessing extra copies results in an elevated risk of autism.

Their research focused on using a method which allows a patients skin cell to be reprogrammed into induced pluripotent stem cells (iPSCs), which can in turn be coaxed into creating any other type of cell. Using this technology, the study authors obtained stem cells from people with schizophrenia who were missing part of 15q11.2 on one of their chromosomes, ultimately coaxing them into neural progenitor cells, which are found in the developing brain.

By observing the process, the researchers found deficiencies during nerve development that could be linked to the gene CYFIP1, which maintains the structure of a nerve cell. By blocking the expression of this gene in developing mouse embryos, they found defects in the formation of the brains cerebral cortex, which plays a key role in consciousness.

The next step was to determine how this gene could interact with other factors, and they discovered that mutations in a pair of genes within a particular cellular pathway linked to CYFIP1 resulted in a significant increase in schizophrenia risk. According to the study authors, their research supports the belief that multiple factors in a single pathway could interact with one another to impact a patients potential risk for psychiatric disorders.

The reason, the team found, is that CYFIP1 plays a role in building the skeleton that gives shape to each cell, and its loss affects spots called adherens junctions where the skeletons of two neighboring cells connect, the university explained. A lack of CYFIP1 protein also caused some of the mice neurons to wind up in the brains wrong layer.

The rest is here:
Johns Hopkins Researchers Locate Genetic Variant Associated With Schizophrenia

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

3-Jul-2014

Contact: Shawna Williams shawna@jhmi.edu 410-955-8236 Johns Hopkins Medicine

Johns Hopkins researchers have begun to connect the dots between a schizophrenia-linked genetic variation and its effect on the developing brain. As they report July 3 in the journal Cell Stem Cell, their experiments show that the loss of a particular gene alters the skeletons of developing brain cells, which in turn disrupts the orderly layers those cells would normally form.

"This is an important step toward understanding what physically happens in the developing brain that puts people at risk of schizophrenia," says Guo-li Ming, M.D., Ph.D., a professor of neurology and neuroscience in the Johns Hopkins University School of Medicine's Institute for Cell Engineering.

While no single genetic mutation is known to cause schizophrenia, so-called genomewide association studies have identified variations that are more common in people with the condition than in the general population. One of these is a missing piece from an area of the genome labeled 15q11.2. "While the deletion is linked to schizophrenia, having extra copies of this part of the genome raises the risk of autism," notes Ming.

For the new study, Ming's research group, along with that of her husband and collaborator, neurology and neuroscience professor Hongjun Song, Ph.D., used skin cells from people with schizophrenia who were missing part of 15q11.2 on one of their chromosomes. (Because everyone carries two copies of their genome, the patients each had an intact copy of 15q11.2 as well.)

The researchers grew the human skin cells in a dish and coaxed them to become induced pluripotent stem cells, and then to form neural progenitor cells, a kind of stem cell found in the developing brain.

"Normally, neural progenitors will form orderly rings when grown in a dish, but those with the deletion didn't," Ming says. To find out which of the four known genes in the missing piece of the genome were responsible for the change, the researchers engineered groups of progenitors that each produced less protein than normal from one of the suspect genes. The crucial ingredient in ring formation turned out to be a gene called CYFIP1.

The team then altered the genomes of neural progenitors in mouse embryos so that they made less of the protein created by CYFIP1. The brain cells of the fetal mice turned out to have similar defects in structure to those in the dish-grown human cells. The reason, the team found, is that CYFIP1 plays a role in building the skeleton that gives shape to each cell, and its loss affects spots called adherens junctions where the skeletons of two neighboring cells connect.

Read more here:
Schizophrenia-associated gene variation affects brain cell development

Recommendation and review posted by simmons

It sounds like something straight out of science fiction: stem cells from donated placentas are being injected into patients with hard-to-heal injuries. The results have been phenomenal, all by taking advantage of something that would be discarded as medical waste.

The stem cells inside a tiny vial will morph into something totally new once injected into the body. Dr. Brett Cascio is the Medical Director of Sports Medicine at Lake Charles Memorial Hospital and he is using this cutting edge technology in some of his toughest cases. We've know the special nature of stem cells for years, decades, he said, but harvesting them and getting them to do what we want them to do is the difficult part.

Dr. Cascio has treated all sorts of injuries - some that just have a tough time healing. For some reason along the way, their healing either stopped or went haywire and they didn't heal correctly, he said, and they need help on the cellular level to heal their problem.

That is where stem cells come in: not from a live human being, but from a donated placenta. The cells are tested, prepared and frozen until needed. One placenta can help hundreds of patients. You don't reject these cells, said Dr. Cascio, your body recognizes them as a potential healing factor and helps it to heal itself.

That healing is something Chad Theriot was desperate to find after rupturing the longest ligament in his foot while playing basketball. I heard a loud pop, he said, and then instant pain. I knew immediately that something was wrong.

Months passed with Theriot on crutches, in a boot, in pain and unable to be the family man he wanted to be. My wife was having to pick up slack everywhere, he said, at home, at work, with the baby.. I wasn't able to help much.

A second opinion brought Theriot to Dr. Cascio. The plan was to inject stem cells into the bottom of Theriot's foot , having them grow into good, healthy tissue in the place of what was damaged. So if you put them in connective tissue or skin, they can grow into skin-type cells or in muscle, they can grow into muscle-type cells, said Dr. Cascio.

Patients are given twilight anesthesia and the injections are given under X-ray guidance. The actual injection only takes one minute. Two weeks later I was taking unassisted steps and my pain level on a scale from one to ten went from an eight to a two, said Theriot.

That was the first time Theriot walked without help in four months. That was a big day for me, he said, that was a big day for us.

This stem cell technology is still in its early stages, but Dr. Cascio says the future is exciting. These are not magical cells, it's not like pixie dust, but they help the body heal itself and you can get some really amazing results, he said.

Read more:
Stem cells from donated placentas healing stubborn injuries

Recommendation and review posted by Bethany Smith

Baby Bridget weighed in at a healthy 7lbs 9oz (3.4kg) at Cork University Maternity Hospital on June 27th when she was born to a couple at risk of having a baby with Cystic Fibrosis. Photograph: Google Street View

The birth of the first baby in the Republic following a technique to screen embryos for genetic conditions such as cystic fibrosis prior to implantation has been hailed as a major milestone for Irish reproductive medicine.

Baby Bridget weighed in at a healthy 7lbs 9oz (3.4kg) at Cork University Maternity Hospital on June 27th when she was born to couple, Lisa Cooke and Patrick Mullane who were at risk of having a baby with Cystic Fibrosis, the most common genetic disease in Ireland.

Dr John Waterstone of the Cork Fertility Centre, which carried out Pre-Implantation Genetic Diagnosis (PGD) on embryos belonging to the couple, explained that Bridgets birth was a highly significant development for couples at risk of having a baby with CF.

We are very pleased to announce the arrival of the first baby after PGD in Ireland - this is a fantastic day for Patrick and Lisa and an important milestone in Irish reproductive medicine, said Dr Waterstone who is also a Consultant Obstetrician at CUMH.

One in 19 Irish adults is a carrier with the altered gene that causes Cystic Fibrosis and approximately one in 400 couples are at risk of having an affected baby but PGD offers couples the opportunity to have an embryo screened for the disease, he said.

PGD allows couples at risk of a specific inherited condition to avoid passing it on to their children. Conception takes place through IVF treatment and embryos are tested for the condition before being transferred, said Dr Waterstone

Head of Research and Development at the Cork Fertility Centre, Dr Xiao Zhang explained that PGD, which costs 9,800, involves a laser assisted embryo biopsy to remove cells for genetic analysis and must be carried out with great precision.

Dr Zhang explained that following the biopsy procedure for Mr Mullane and Ms Cooke, the embryos were frozen by means of vitrification with Ms Cooke returning later to have one embryo transferred into the uterus.

We are delighted by todays success; it is the result of a lot of hard work over the past few years validating and perfecting the underlying laboratory processes, said Dr Zhang, adding that the Cork Fertility Centre was one of only two Irish IVF units to have attempted PGD.

Read more here:
Birth of first baby screened for Cystic Fibrosis a milestone

Recommendation and review posted by Bethany Smith

Understanding the Link Between Genetics and CLL Drug Resistance
Chronic lymphocytic leukemia (CLL) experts continue to research the potential for a patient to become resistant to new and developing inhibitor CLL treatment...

By: Patient Power

Read the original post:
Understanding the Link Between Genetics and CLL Drug Resistance - Video

Recommendation and review posted by Bethany Smith

Spinal Cord Injury 3: Nerve Transfers in the Tetraplegic Upper Limb
Nerve transfer surgery has revolutionized peripheral nerve surgery. The application of nerve transfer surgery to incomplete tetraplegia offers exciting recon...

By: Dominic Power

Read the original here:
Spinal Cord Injury 3: Nerve Transfers in the Tetraplegic Upper Limb - Video

Recommendation and review posted by sam

Swansea University Soapbox Science - Ina Laura Pieper, Regenerative Medicine
Soapbox Science is an annual public science communication event that transforms public areas into an arena for public learning and scientific debate without PowerPoint slides. It provides an...

By: Swansea Uni

Read the rest here:
Swansea University Soapbox Science - Ina Laura Pieper, Regenerative Medicine - Video

Recommendation and review posted by sam

Regenerative Medicine Market in the US 2014 2018
Complete Report is Available @ http://www.sandlerresearch.org/regenerative-medicine-market-in-the-us-2014-2018.html . The Regenerative Medicine market in the US can be divided into 11 segments:...

By: Stacy Banks

Continue reading here:
Regenerative Medicine Market in the US 2014 2018 - Video

Recommendation and review posted by sam

By Ben Spencer

Published: 09:48 EST, 4 July 2014 | Updated: 10:20 EST, 4 July 2014

Fat removed from a heart attack patient during cardiac surgery could be re-injected into their chest to lower the risk of repeat problems, research suggests.

Scientists think that stem cells in fatty tissue could be extracted and inserted directly into the heart, reducing the chance of future attacks.

The stem cells - blank cells capable of acting as a repair kit for the body by replacing worn-out tissue - can improve the functioning of the heart and strengthen crucial arteries and veins, the researchers found.

Usually most of the fat that is found during open heart surgery is removed and then discarded.

Scientists believe fat removed from a heart attack patient during cardiac surgery could be re-injected into their chest to lower the risk of repeat problems. Stock image

But the new study suggests that the fat could be retained and the useful stem cells isolated and injected back into the heart - all while the patient is still on the operating table.

Canadian cardiologist Dr Ganghong Tian, who will present his findings at a European Society of Cardiology conference in Barcelona tomorrow (Sunday), said: During cardiac surgery fat tissue may need to be removed from patients to expose the heart.

We were intrigued to find out whether this mediastinal fat, which would otherwise be discarded, contained stem cells that could be injected back into the heart before closing the chest.

Read the original:
Fat cells removed from heart attack patients could be re-injected into their chest to help repair the organ ...

Recommendation and review posted by Bethany Smith